Patients who ask their clinic about peptides are about to get a new answer, and it needs careful wording. On 28 October 2026, the U.S. Department of Health and Human Services (HHS) filed a policy saying the Food and Drug Administration (FDA) will not take enforcement action against eligible compounders of six peptides that have never been approved as drugs. The move brings a market that has largely operated through online sellers of so-called research-use-only products into licensed pharmacies, but it does not turn any of the six substances into an approved medicine, and the evidence for their safety and effectiveness remains, in the FDA's own scientists' assessment, insufficient.
What the Policy Changes
The document, titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances and filed as Federal Register document 2026-22192, is scheduled for publication on 30 October 2026, with comments open for two weeks after publication under docket HHS-OASH-2026-0496. In it, HHS says there is significant interest in the use of these peptides in compounding, given the lack of available approved products, and that it therefore does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician compounding a drug product using one of the listed peptides. The policy is interim: it applies while the FDA develops, through rulemaking, the list of bulk drug substances that may be used in compounding under section 503A, which is the part of the law that lets smaller pharmacies compound medicines for individual patients without full FDA approval, manufacturing-practice compliance or standard labelling, provided set conditions are met. Compounders covered by the policy must still follow basic rules on ingredient quality, manufacturing, safety reporting, labelling and prescriptions written for individual patients, and must report serious adverse events and product-quality problems such as contamination to the FDA.
The policy's stated rationale is harm reduction as much as access. HHS and its supporters argue that patients are already buying peptides from unregulated online sources, often sourced overseas, and that a licensed pharmacy, with pharmacist oversight and adverse-event reporting, is a more accountable channel than a vial labelled for research use only. The Alliance for Pharmacy Compounding welcomed the decision on those grounds, saying it brings patients into a system where pharmacy standards, regulatory oversight and serious adverse-event reporting apply. But the same announcement drew sharp criticism: Public Citizen said the decision lets unproven and potentially unsafe peptides be made, marketed and prescribed without concern about federal enforcement, and the Partnership for Safe Medicines, which had filed a citizen petition the previous week urging the FDA to reject the advisory committee's recommendation, said the decision leaves Americans in a grey area over whether peptides are safe, even though the FDA's own scientists had recommended against the move.
The Six Peptides and Their Reported Uses
The six peptides named in the policy, and the uses their promoters cite for them, are:
- BPC-157, promoted for ulcerative colitis and tissue repair;
- Epitalon, promoted for insomnia;
- KPV, promoted for wound healing and inflammatory conditions;
- MOTS-c, promoted for metabolic health, obesity and osteoporosis;
- Semax, promoted for migraine and chronic pain;
- TB-500, promoted for wound healing, often discussed together with BPC-157.
None of these uses is an FDA-approved indication, and none of the six is an approved drug. Peptides are short chains of amino acids, shorter than proteins, and they have grown sharply in popularity over the past year, driven by endorsements from wellness influencers and some clinicians, for purposes ranging from anti-ageing to muscle recovery and tissue repair. Health Secretary Robert F. Kennedy Jr., who signed the policy, has described himself as a supporter of peptides and has said he has used some himself. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted in favour of expanded access to all six peptides through compounding, while the FDA's own scientists recommended against unwinding the existing restrictions at the same meeting.
What the Policy Does Not Do
Four limits deserve emphasis, because headlines have blurred them. First, the policy is not an approval and not a final rule: it is an interim enforcement position, it creates no legal rights, and HHS says it may revisit it, in whole or in part, if a safety signal or a product-quality issue arises. Second, it does not cover the larger outsourcing facilities that compound under section 503B and produce medicines at higher volumes, so supply will come only from smaller 503A pharmacies, in small quantities. One compounding company president told NPR his firm would likely compound only one of the six peptides at first and did not expect the country's 503A pharmacies, collectively, to meet demand. Third, it does not settle the scientific question: the FDA has not reviewed these compounded products for safety, effectiveness or quality before marketing, and the advisory committee's vote does not change that. Fourth, it does not end the regulatory process: the formal rulemaking that will decide whether any of the six joins the 503A bulk-substances list is still to come, and the two-week comment window is the public's opportunity to weigh in.
What This Means for Compounding Pharmacies
For clinics, the immediate effect is conversational, not clinical: patients will arrive asking about peptides they have seen promoted online, and front-desk and clinical teams need a consistent, accurate answer. The safe framing is the policy's own: these products are now compoundable by eligible pharmacies under enforcement discretion, but they are not FDA-approved, their benefits are unproven, and their risks, including contamination and other adverse effects, are real. Practices that discuss peptides with patients should document those conversations, avoid promising outcomes the evidence does not support, and make sure patients understand the difference between a compounded product and an approved drug. Prescribers should also expect practical friction: ingredient suppliers must first verify that their active ingredients meet the policy's requirements, and pharmacies must verify that too, so products may take time to become available, and supply may be uneven. Organisations with pharmacy partners should confirm, before referring patients, which peptides a given pharmacy actually compounds, under what quality controls, and how adverse events will be reported.
Analysis: Access First, Evidence Later
This policy inverts the usual order of drug regulation: access comes first, and the evidence review follows, if it follows at all. The argument for that order is pragmatic, and not frivolous: a grey market already exists, it is unmonitored, and a licensed pharmacy is plainly a better place for a patient to obtain a substance than an anonymous website. The argument against it is equally plain: enforcement discretion removes the main deterrent that kept these products out of mainstream medicine, without producing any new evidence that they work or are safe, and it does so over the documented objections of the agency's own scientists. What will decide which argument ages better is what happens next: whether adverse-event reporting surfaces problems quickly, whether the formal rulemaking imposes real quality standards or simply ratifies the interim position, and whether clinicians hold the line in the consulting room between what is now permitted and what is actually proven. Clinics should watch the comment window and the rulemaking, not just the headlines, because the interim policy is explicitly revisable, and its final form is still unwritten.
Clinics preparing patient-facing answers on fast-moving policy changes, and the intake and messaging workflows that carry those conversations, can explore MedClinicX's AI patient portal, see how after-hours calls are handled on our AI medical receptionist page, or explore the demos and request a quote for their own practice.
Sources and References
- Federal Register, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, public inspection document 2026-22192, filed 28 October 2026, scheduled for publication 30 October 2026: https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- NPR, Trump administration will allow pharmacies to make popular peptides, 28 October 2026: https://www.cfpublic.org/2026-10-28/trump-administration-will-allow-pharmacies-to-make-popular-peptides
- Reuters, US Health Secretary Kennedy opens access to some unapproved peptides, 28 October 2026: https://943jackfm.com/2026/10/28/us-health-department-to-allow-temporary-sale-of-some-unapproved-peptides/
Reporting based on the sources above, accessed 29 October 2026. The Federal Register public inspection document and the NPR report were read directly in full, and the Reuters report was cross-checked against them. MedClinicX did not conduct original reporting or interviews for this article. This article is for information only and is not medical advice. Corrections: contact us via https://medclinicx.com/contact